News

May 25, 2018May 25, 2018

Quizartinib Prolongs Survival in Some Patients with Relapsed or Refractory AML, Phase 3 Study Shows

News

Quizartinib, an inhibitor of the FLT3 molecule, significantly prolongs overall survival compared to salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) carrying FLT3-ITD mutations, and ... Read more

May 23, 2018May 23, 2018

Tecentriq-Cotellic Combo Fails to Lengthen Survival in Advanced Colorectal Cancer

News

A combination treatment of Tecentriq (atezolizumab) and Cotellic (cobimetinib) did not extend survival of patients with advanced or difficult-to-treat colorectal cancer (CRC) compared to standard therapy, Roche’s Phase 3 ... Read more

May 22, 2018

Phase 1 Trial on Treos’ Potential Colorectal Cancer Vaccine Doses First Patient

News

A Phase 1 trial evaluating the investigational colorectal cancer vaccine PolyPEPI 1018 in patients whose disease has metastasized has begun dosing participants, Treos Bio announced. The trial (NCT03391232), which is still recruiting, ... Read more

May 18, 2018

Eli Lilly Acquires Pegilodecakin, Potential Immunotherapy Now in Phase 3 Trial

News

Eli Lilly announced that it is acquiring ARMO BioSciences and its lead treatment candidate pegilodecakin (AM0010), an investigational immunotherapy that has shown clinical benefit in multiple types of cancer and is now in a ... Read more

May 16, 2018May 16, 2018

Humanized CAR T-cell Therapy Seen to Treat Metastatic Colorectal Cancer in Mouse Study

News

A humanized chimeric antigen receptor (CAR) T-cell immunotherapy was seen successfully kill tumor cells and prevent further spread of colorectal metastatic cancer in mouse models of the disease. The treatment, ... Read more

May 15, 2018May 15, 2018

FDA Grants Priority Review to Tecentriq Combo for First-Line Treatment of Advanced Lung Cancer

News

The U.S. Food and Drug Administration has granted priority review to Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy medications Taxol (paclitaxel) and carboplatin for first-line treatment of metastatic non-squamous ... Read more

May 11, 2018

Canada Approves Imfinzi for Advanced, Inoperable Non-small Cell Lung Cancer

News

Health Canada recently approved Imfinzi (durvalumab) for the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), AstraZeneca Canada announced. The approval is for patients with stage ... Read more

May 9, 2018May 9, 2018

Researchers May Now Predict Which CLL Patients Will Respond to Kymriah CAR T-Cell Therapy, Study Says

News

The absence of a specific T-cell subset may help explain why three in four patients with advanced chronic lymphocytic leukemia (CLL) fail to respond to Kymriah (tisagenlecleucel) — a CAR ... Read more

May 8, 2018

Study Evaluating VBI-1901 Enrolling Recurrent GBM Patients in Second Dose Group

News

An Independent Data and Safety Monitoring Board (DSMB) unanimously recommended that the Phase 1/2 clinical trial evaluating VBI Vaccines’ VBI-1901 continue to enroll patients with recurrent glioblastoma (GBM) in ... Read more

May 4, 2018

Advanced Melanoma Patients Seen to Respond to CMP-001, Keytruda Combo in Ongoing Study

News

Intratumoral injection of CMP-001 in combination with Keytruda (pembrolizumab) worked to reduce tumor burden in advanced melanoma patients whose disease failed to respond, or progressed, when treated with PD-1 inhibitors, ... Read more

Pin It on Pinterest